|Bid||9.26 x 800|
|Ask||9.28 x 900|
|Day's Range||9.07 - 9.44|
|52 Week Range||8.01 - 21.71|
|Beta (3Y Monthly)||2.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.90|
NEWTON, Mass., Feb. 07, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee.
Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 428,500 shares of Karyopharm’s common stock to eighty-three newly-hired employees, with a grant date of January 31, 2019. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $8.47 per share, the closing price of Karyopharm’s common stock on January 31, 2019. Each stock option vests over four years, with 25% of the original number of shares underlying the stock option vesting on the one-year anniversary of the applicable employee’s employment commencement date and an additional 1/48th of the shares vesting monthly thereafter, subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.
NEWTON, Mass., Jan. 08, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Karyopharm Therapeutics Inc. (NASDAQ:KPTI), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
NEWTON, Mass., Jan. 02, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief.
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors’ favor when it comes to beating the market, […]
-- Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in.
CORAL GABLES, FL / ACCESSWIRE / December 3, 2018 / Attention on Healthcare Market has continued to accelerate this quarter. The global healthcare IT market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by Technavio.
Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. The data were highlighted in a poster presentation at the American Society of Hematology (ASH) 2018 Annual Meeting in San Diego.
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 10.23% and -80.25%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Newton, Massachusetts-based company said it had a loss of 79 cents per share. The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
I’ve been keeping an eye on Karyopharm Therapeutics Inc (NASDAQ:KPTI) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...